Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Can Autologous Adipose Tissue Derived Stromal Cells Be Used for Cell Therapy in Multiple Myeloma?

ABSTRACT: Can Autologous Adipose Tissue Derived Stromal Cells Be Used for Cell Therapy in Multiple Myeloma?

PROVIDER: PRJNA534286 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Functional comparison between healthy and multiple myeloma adipose stromal cells

Project description:Multiple myeloma (MM) is a not curable B-cell neoplasia characterised by the accumulation of tumor plasma cells within the bone marrow. As a consequence, 80% of patients develop bone osteolytic lesions that remain even after complete remission. We and others had demonstrated that bone marrow derived Mesenchymal Stromal Cells (MSC) are abnormal in MM and thus could not be used for an autologous treatment to repare bone damages. Adipose Stromal Cells (ASC) represent an interesting alternative to MSC for cellular therapy. Thus, in this paper we asked if they could be a good candidate in repairing MM bone lesions. For the first time, we present a transcriptomic, phenotypic and functional comparison between ASC from MM patients and healthy donors (HD) relying on their autologous MSC counterpart. In contrast to MM MSC, MM ASC do not exhibit major abnormalities. However, the changes observed in MM ASC and the supportive property of ASC on MM cells question their putative and safety uses at autologous or allogenic level.

2019-06-27 | GSE133346 | GEO

Functional comparison between healthy and multiple myeloma adipose stromal cells

Project description:Functional comparison between healthy and multiple myeloma adipose stromal cells

| PRJNA551223 | ENA

Interaction with Myeloma Suppresses Ciliogenesis and osteogenesis of Bone Marrow Stromal Cells

Project description:Impaired bone marrow stromal cells (BMSCs) within the bone niche of multiple myeloma (MM) patients are implicated in the development of myeloma bone disease (MBD) and disease progression. However, the specific mechanisms are not yet fully understood.

2024-04-19 | GSE263960 | GEO

An IL-1β driven neutrophil-stromal cell axis fosters a BAFF-rich microenvironment in multiple myeloma

Project description:Neutrophils are the most abundant nucleated cell type in the bone marrow. A pro-tumor bias in this cell type may have implications for bone-marrow residing malignancies, such as multiple myeloma. Here, we generated single cell transcriptomic overviews of the entire myeloid compartment, including the entire neutrophilic lineage, of the bone marrow of 6 newly diagnosed myeloma patients, 5 treated myeloma patients and 4 non-cancer controls. We find dat mature neutrophils in myeloma patients, both newly diagnosed and treated, have an activated and pro-inflammatory phenotype, accompanied by increased transcription of pro-inflammatory cytokines, such as IL-1β, and myeloma cell survival factors, such as BCMA-ligand BAFF/TNFSF13B. Moreover, inflammatory stromal cells can activate naive neutrophils to acquire an inflammatory phenotype as is seen in patients. Previously, we have shown that inflammatory stromal cells characterized the bone marrow of newly diagnosed myeloma patients. Here, we generate single cell RNA sequencing dataset of non-hematopoietic bone marrow cells of patients after induction treatment, high-dose melphalan, stem cell transplantation and consolidation treatment. We show that this intensive treatment reduced, but did not normalize, stromal inflammation.

2023-03-31 | E-MTAB-12760 | biostudies-arrayexpress

Gene expression analysis of bone marrow stromal cells from multiple myeloma patients and controls

Project description:Multiple myeloma is hematologic malignancies result from clonal proliferation of plasma cells. Recently, increasing evidence supports the hypothesis that microenvironment cells play important roles in the proliferation, survival, and drug resistance of clonal plasma cells. The aim of this study is to culture stromal cells from bone marrow aspirates of patients with multiple myeloma, and to investigate expression profiles of bone marrow stromal cells and their relationships with the clinical characteristics of patients. RNA was extracted cultured bone marrow stromal cells from 15 patients with plasma cell neoplasms, and bone marrow stromal cells from 13 control patients with 9 B-cell lymphoma patients with no evidence of BM involvement and 4 patients with mild-to-moderate cytopenia without evidence of hematologic malignancies

2016-08-20 | E-GEOD-85837 | biostudies-arrayexpress

Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease [methylation]

Project description:Genome wide DNA methylation profiling of bone marrow-derived mesenchymal stromal cells from healthy donors (n=11), monoclonal gammopathy of undetermined significance (MGUS) (n=10), smoldering myeloma (SMM) (n=8), multiple myeloma (MM) (n=9) patients, and healthy donors exposed to the MM.1S cell line (n=3). The Illumina Infinium MethylationEPIC Beadchip was used to obtain DNA methylation profiles across approximately 850,000 CpGs in this cell type.

2020-11-25 | GSE137360 | GEO

Bone Marrow Stromal Cell Induced Chromatin Remodeling and Associated Transcriptional Changes in Multiple Myeloma [RNA-Seq]

Project description:Differential gene expression analysis of three multiple myeloma cell lines without stromal co-culture (control) with stromal co-culture (condition) after 72 hours of exposure.

2024-02-25 | GSE220143 | GEO

Bone Marrow Stromal Cell Induced Chromatin Remodeling and Associated Transcriptional Changes in Multiple Myeloma [ATAC-Seq]

Project description:Differential chromatin accessibility analysis of three multiple myeloma cell lines without stromal co-culture (control) with stromal co-culture (condition) after 72 hours of exposure.

2024-02-25 | GSE220142 | GEO

Gene expression analysis of bone marrow stromal cells from multiple myeloma patients and controls

2016-08-20 | GSE85837 | GEO

Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease [methylation II]

2020-11-25 | GSE137416 | GEO